Lv5
1486 积分 2022-07-11 加入
Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials
3天前
已完结
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial
4天前
已完结
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma
9天前
已完结
Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma
15天前
已完结
Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma
15天前
已完结
Metabolomic aging and mortality clocks based on ensemble learning identify systemic aging risk across the human life span in 18,476 individuals
18天前
已完结
A single-cell atlas of multiple myeloma defines malignant archetypes and proliferative states
20天前
已完结
Lifestyle-induced regulatory T cell fragility primes adverse events after immune checkpoint blockade
27天前
已完结
OA-27 Fifteen-Month Follow-Up from a Pivotal Trial of GR1803 in Patients with Relapsed/Refractory Multiple Myeloma
28天前
已完结
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
1个月前
已完结